IDF Diabetes Atlas,10th ed. International Diabetes Federation; 2021.

Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–98. https://pubmed.ncbi.nlm.nih.gov/30288571. https://doi.org/10.1007/s00125-018-4729-5.

Mahajan R. Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes. Indian J Pharmacol. 2009;41(4):197-8. https://pubmed.ncbi.nlm.nih.gov/20523873. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875741. https://doi.org/10.4103/0253-7613.56070.

Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: A novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23(8):1154–61. https://pubmed.ncbi.nlm.nih.gov/10937514. https://doi.org/10.2337/diacare.23.8.1154,

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://pubmed.ncbi.nlm.nih.gov/33782057. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005924. https://doi.org/10.1136/bmj.n71.

U.S. Food and Drug Administration. MedWatch: The FDA safety information and adverse event reporting program. Accessed Aug 29, 2022. www.fda.gov/medwatch.

Cochrane Handbook. Obtaining standard deviations from standard errors and confidence intervals for group means. Accessed Sep 29, 2022. https://handbook-5-1.cochrane.org/chapter_7/7_7_3_2_obtaining_standard_deviations_from_standard_errors_and.htm.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17(1):1–12. https://pubmed.ncbi.nlm.nih.gov/8721797. https://doi.org/10.1016/0197-2456(95)00134-4.

Higgins J, Green S. Cochrane handbook for systematic reviews of Interventions. www.cochrane-handbook.org.

Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6. https://pubmed.ncbi.nlm.nih.gov/18436948. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2335261. https://doi.org/10.1136/bmj.39489.470347.AD.

Santesso N, Glenton C, Dahm P, , et al. GRADE guidelines 26: Informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126–35. https://pubmed.ncbi.nlm.nih.gov/31711912. https://doi.org/10.1016/j.jclinepi.2019.10.014.

Singh A, Hussain S, Najmi AK. Number of studies, heterogeneity, generalisability, and the choice of method for meta-analysis. J Neurol Sci. 2017;381:347. https://pubmed.ncbi.nlm.nih.gov/28967410. https://doi.org/10.1016/j.jns.2017.09.026.

Sedgwick P. Meta-analyses: What is heterogeneity? BMJ. 2015;350:h1435. https://pubmed.ncbi.nlm.nih.gov/25778910. https://doi.org/10.1136/bmj.h1435.

Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res Paediatr. 2004;62(2):55–9. https://pubmed.ncbi.nlm.nih.gov/15205563. https://doi.org/10.1159/000078932.

Vinik AI, Cincotta AH, Scranton RE, Bohannon N, Ezrokhi M, Gaziano JM. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012;18(6):931–43. https://pubmed.ncbi.nlm.nih.gov/23186965. https://doi.org/10.4158/EP12187.OR.

Liang W, Gao L, Li N, et al. Efficacy and safety of bromocriptine-qr in type 2 diabetes: A systematic review and meta-analysis. Horm Metab Res. 2015;47(11):805–12. https://pubmed.ncbi.nlm.nih.gov/26332757. https://doi.org/10.1055/s-0035-1559684.

Shivaprasad C, Kalra S. Bromocriptine in type 2 diabetes mellitus. Indian J Endocrinol Metab. 2011;15(5):17. https://pubmed.ncbi.nlm.nih.gov/21847449. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152192. https://doi.org/10.4103/2230-8210.83058.

Kalra S, Kalra B, Agrawal N, Kumar S. Dopamine: The forgotten felon in type 2 diabetes. Recent Pat Endocr Metab Immune Drug Discov. 2011;5(1):61–5. https://pubmed.ncbi.nlm.nih.gov/22074579. https://doi.org/10.2174/187221411794351842.

Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology. 1999;70(6):460–5. https://pubmed.ncbi.nlm.nih.gov/10657739. https://doi.org/10.1159/000054508.

Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: A new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999;8(10):1683–707. https://pubmed.ncbi.nlm.nih.gov/11139820. https://doi.org/10.1517/13543784.8.10.1683.

DeFronzo RA. Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34(4):789–94. https://pubmed.ncbi.nlm.nih.gov/21447659. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064029. https://doi.org/10.2337/dc11-0064.

Luo S, Meier AH, Cincotta AH. Bromocriptine Reduces Obesity, Glucose Intolerance and Extracellular Monoamine Metabolite Levels in the Ventromedial Hypothalamus of Syrian Hamsters. Neuroendocrinology. 1998;68(1):1–10. https://pubmed.ncbi.nlm.nih.gov/9695933. https://doi.org/10.1159/000054344.

Chamarthi B, Gaziano JM, Blonde L, et al. Timed bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus. J Diabetes Res. 2015;2015:157698. https://pubmed.ncbi.nlm.nih.gov/26060823. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4427775. https://doi.org/10.1155/2015/157698.

Cincotta AH, Cersosimo E, Alatrach M, et al. Bromocriptine-QR therapy reduces sympathetic tone and ameliorates a pro-oxidative/pro-inflammatory phenotype in peripheral blood mononuclear cells and plasma of type 2 diabetes subjects. Int J Mol Sci. 2022;23(16):8851. https://pubmed.ncbi.nlm.nih.gov/36012132. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407769. https://doi.org/10.3390/ijms23168851.

Gaziano JM, Cincotta AH, O’Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33(7):1503–8. https://pubmed.ncbi.nlm.nih.gov/20332352. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890350. https://doi.org/10.2337/dc09-2009.

Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R. Effect of bromocriptine‐QR (a quick‐release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012;1(5): e002279. https://pubmed.ncbi.nlm.nih.gov/23316290. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541616. https://doi.org/10.1161/JAHA.112.002279.

Chamarthi B, Ezrokhi M, Rutty D, Cincotta AH. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin. Postgrad Med. 2016;128(8):761–9. https://pubmed.ncbi.nlm.nih.gov/27687032. https://doi.org/10.1080/00325481.2016.1243003.

Schäfer M, Browne LP, Truong U, et al. Bromocriptine improves central aortic stiffness in adolescents with type 1 diabetes: Arterial health results from the BCQR-T1D study. Hypertension. 2022;80(2):482-91. https://pubmed.ncbi.nlm.nih.gov/36472197. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852005. https://doi.org/10.1161/HYPERTENSIONAHA.122.19547.

Franchi F, Lazzeri C, Barletta G, Ianni L, Mannelli M. Centrally mediated effects of bromocriptine on cardiac sympathovagal balance. Hypertension. 2001;38(1):123–9. https://pubmed.ncbi.nlm.nih.gov/11463772. https://doi.org/10.1161/01.hyp.38.1.123.

Sowers JR. Dopaminergic control of circadian norepinephrine levels in patients with essential hypertension. J Clin Endocrinol Metab. 1981;53(6):1133–7. https://pubmed.ncbi.nlm.nih.gov/7298797. https://doi.org/10.1210/jcem-53-6-1133.

Alatrach M, Agyin C, Adams J, et al. Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetes. Endocrinol Diabetes Metab. 2018;1(4):e00034. https://pubmed.ncbi.nlm.nih.gov/30815562. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354804. https://doi.org/10.1002/edm2.34.

Via MA, Chandra H, Araki T, Potenza MV, Skamagas M. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2010;3:43-8. https://pubmed.ncbi.nlm.nih.gov/21437075. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047985. https://doi.org/10.2147/dmsott.s9575.

Ramteke KB, Ramanand SJ, Ramanand JB, et al. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Indian J Endocrinol Metab. 2011;15(5):S33-9. https://pubmed.ncbi.nlm.nih.gov/21847452. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152182. https://doi.org/10.4103/2230-8210.83062.

Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 199;19(6):667–70. https://pubmed.ncbi.nlm.nih.gov/8725871. https://doi.org/10.2337/diacare.19.6.667.

Kamath V, Jones CN, Yip JC, et al. Effects of a quick-release form of bromocriptine (ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care. 1997;20(11):1697–701. https://pubmed.ncbi.nlm.nih.gov/9353611. https://doi.org/10.2337/diacare.20.11.1697.

Briones-Aranda A, Ramírez-Carballo J, Gómez BAR, et al. Influence of bromocriptine plus metformin treatment on glycaemia and blood pressure in patients with type 2 diabetes mellitus. Rom J Diabetes Nutr Metab Dis. 2018;25(1):59–66. https://www.rjdnmd.org/index.php/RJDNMD/article/view/459.

Chamarthi B, Cincotta AH. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin. Postgrad Med. 2017;129(4):446–55. https://pubmed.ncbi.nlm.nih.gov/28374645. https://doi.org/10.1080/00325481.2017.1315290.

Ghosh A, Sengupta N, Sahana P, Giri D, Sengupta P, Das N. Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial. Indian J Pharmacol. 2014;46(1):24-8. https://pubmed.ncbi.nlm.nih.gov/24550580. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912802. https://doi.org/10.4103/0253-7613.125160.